Publications by authors named "Lourdes M Perez-Chada"

Multidisciplinary care is essential for the management of patients with psoriatic disease (PsD), considering the great range of cutaneous and musculoskeletal symptoms and the potential for associated comorbidities and extraarticular manifestations. Consequently, combined rheumatology/dermatology clinics represent a gold standard model of care for patients with PsD. Many challenges are associated with the establishment of these clinics in routine clinical practice.

View Article and Find Full Text PDF

During the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, the International Dermatology Outcome Measures (IDEOM) psoriatic disease (PsD) workgroup presented an update on their efforts toward measurement of musculoskeletal (MSK) symptoms in patients with PsD. Dr. Joseph Merola initiated the presentation emphasizing the vital importance of assessing MSK symptoms in patients with psoriasis (PsO) regardless of whether they have been diagnosed with psoriatic arthritis (PsA).

View Article and Find Full Text PDF

The nonprofit organization International Dermatology Outcome Measures (IDEOM) is committed to improving the implementation of patient-centered outcome measures in dermatologic disease. At a conference adjacent to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, the IDEOM Psoriatic Disease Workgroup presented updates on recent efforts in outcome measure advancement. Dr.

View Article and Find Full Text PDF
Article Synopsis
  • Psoriatic disease is often overlooked, so researchers created the Psorcast app, which uses smartphone sensors to let patients self-measure their skin and joint symptoms.
  • During the study, nearly half of the 104 participants had psoriatic arthritis, and the app showed a strong correlation with traditional physician assessments for skin involvement.
  • The app’s results are promising, but more research with larger groups is needed before it can be used more widely in clinical practice, and the technology is open-source for public access.
View Article and Find Full Text PDF
Article Synopsis
  • * Early diagnosis and treatment of PsA can significantly improve patient outcomes and quality of life, making it crucial for healthcare providers to screen for this condition.
  • * Choosing the right therapy involves considering various factors like disease severity, patient preferences, coexisting conditions, and medication access, with a focus on addressing multiple aspects of the patient's psoriatic disease.
View Article and Find Full Text PDF

Psoriatic arthritis (PsA) is an inflammatory seronegative arthritis strongly associated with psoriasis. Recognition of the clinical features of PsA is critical, as delayed detection and untreated disease may result in irreparable joint damage, impaired physical function, and a significantly reduced quality of life. Dermatologists are poised for the early detection of PsA, as psoriasis predates its development in as many as 80% of patients.

View Article and Find Full Text PDF
Article Synopsis
  • Early detection and effective management of psoriatic arthritis (PsA) in psoriasis patients are crucial yet often overlooked medical needs.
  • The study compared patients with psoriasis who screened positive for PsA using the Psoriasis Epidemiology Screening Tool (PEST) to those with confirmed PsA and those who screened negative, analyzing demographics, disease impact, and symptom states.
  • Results showed that screen-positive and PsA patients had similar disease profiles, with a significant proportion reaching an acceptable symptom state, highlighting the importance of screening for PsA in psoriasis patients.
View Article and Find Full Text PDF

Patients with autoimmune bullous diseases are at an increased risk of infection, both from the underlying skin disease and from immunosuppressive treatments. Limited information is available on vaccine beliefs and behaviors in dermatology patients and adults with autoimmune bullous diseases in particular. To understand vaccine decision making, identify perceived risks and benefits of vaccinations, and discuss individual experiences in patients with autoimmune bullous diseases in the United States.

View Article and Find Full Text PDF
Article Synopsis
  • Interleukin-4 (IL-4) therapies are changing how inflammatory skin conditions are treated.
  • These targeted therapies focus specifically on IL-4, leading to better outcomes for patients.
  • The advancements in IL-4 treatments represent a significant improvement in managing various inflammatory dermatoses.
View Article and Find Full Text PDF

Importance: Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis. Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use.

Objective: To systematically review the validity of HRQL-focused PROMs used in patients with psoriasis.

View Article and Find Full Text PDF

Vaccination rates among adults in the United States, including dermatology patients, remain suboptimal. Previous research has concluded that outpatient specialty offices often have administrative and patient-related barriers to administering vaccines in their clinics, however, this has never been examined specifically in dermatology. This study aims to examine dermatologists' perspectives on vaccine education in dermatology clinics, identify facilitators and barriers to vaccine administration in dermatology clinics, and explore strategies to improve vaccination rates in dermatology patients.

View Article and Find Full Text PDF

The International Dermatology Outcome Measures (IDEOM) organization presented an update on its progress related to patient-centered outcome measures for psoriasis (PsO) and psoriatic arthritis (PsA) at the 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Musculoskeletal (MSK) Symptoms working group presented an update on the development of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q). The IDEOM MSK-Q is a patient-reported outcome measure intended to capture MSK symptoms and describe their intensity and impact on health-related quality of life in patients with psoriatic disease.

View Article and Find Full Text PDF

Objective: The aim of this systematic review and metaanalysis is to summarize evidence regarding the relationship between psoriatic arthritis (PsA) and sleep problems.

Methods: We identified 36 eligible studies-26 cross-sectional, 7 cohort, and 3 interventional studies-in PubMed and Embase.

Results: The prevalence of self-reported sleep problems in patients with PsA ranged from 30% to 85%.

View Article and Find Full Text PDF

Background: Alopecia areata (AA) is a disease of hair loss with multiple treatment options. Physicians play an important role in guiding patients during the decision-making process.

Objective: Assess physicians' values and attitudes when helping patients choose an AA treatment.

View Article and Find Full Text PDF

Having a chronic disease is one of the most consistent factors associated with vaccine uptake for adults in the general population, but vaccination beliefs and behaviors specific to those with chronic skin diseases have not been explored. The objective of this study was to explore factors associated with vaccine uptake and barriers to vaccination in adults with psoriasis and eczema. Virtual, video-based semi-structured interviews were performed with adults who self-reported a diagnosis of psoriasis or eczema.

View Article and Find Full Text PDF

Background: Alopecia areata (AA) is a disease of hair loss in which patients may benefit from comprehensive understanding of AA's disease process and therapeutic options during treatment decision-making.

Objective: Determine factors influencing patients' AA treatment decision-making.

Methods: Qualitative interviews were conducted using semi-structured interview guides.

View Article and Find Full Text PDF

Importance: Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQoL) exist for patients with acne. However, little is known about the content validity and other measurement properties of these PROMs.

Objective: To systematically review PROMs for HRQoL in adults or adolescents with acne.

View Article and Find Full Text PDF

The International Dermatology Outcome Measures (IDEOM) initiative presented an update on their progress related to instruments for psoriasis (PsO) and psoriatic arthritis (PsA) patient-centered outcome measures at the 2021 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Treatment Satisfaction working group presented the development of a 7-item treatment satisfaction questionnaire specific for dermatological conditions. The group is beginning by assessing the validity and reliability of the instrument in PsO patient populations, with the ultimate goal of validating it for use in multiple dermatological diseases.

View Article and Find Full Text PDF

Objective: The lack of standardised outcomes and outcome measures for cutaneous lupus erythematosus (CLE) represents a substantial barrier to clinical trial design, comparative analysis and approval of novel investigative treatments. We aimed to develop a working core outcome set (COS) for CLE randomised controlled trials and longitudinal observational studies.

Methods: We conducted a multistage literature review of CLE and SLE studies to generate candidate domains and outcome measures.

View Article and Find Full Text PDF

Importance: Rising costs of topical steroids have increased overall health care and patient out-of-pocket costs while increasing administrative burden on dermatologists and office staff.

Objective: To explore factors affecting the decision-making process for dermatologists around topical steroid prescriptions, determine the association of insurance coverage and cost, and assess willingness to implement solutions to decrease out-of-pocket topical steroid costs for patients.

Design, Setting, And Participants: This qualitative study was conducted from June to November 2020 and used semistructured interviews of 16 dermatologists who reflected a mix of physicians in academic, nonacademic, and private practice until thematic saturation was reached.

View Article and Find Full Text PDF